CRL Charles River Laboratories
$304.96 -1.87%
US Stock · Health Care
RSI (14) · 30 / 70 bands
MACD (12, 26, 9)
Solid = close · dashed = 50-day MA · bars = volume. Toggle Bollinger / RSI / MACD. Hover to inspect. EOD data.
1D
-1.87%
YTD
+79.30%
P/E
—
P/B
3.16
ROE
-7.7%
Div yield
—
Beta
1.24
Market cap
$13.8B
RSI (14)
62
Next earnings
Nov 3, 2026
Previous session
close of Oct 6, 2026 · EOD, no live order bookOpen
$319.80
Close
$304.96
VWAP (n/a)
—
Day high
$333.30
Day low
$300.01
Volume
1.9M
VWAP = daily turnover ÷ volume — the volume-weighted average, the closest EOD read on where trading actually clustered. A true order book is live-only and needs a broker feed. Turnover/VWAP available for MOEX listings.
Latest headlines
Charles River and Autolomous Partner to Transform Laboratory Execution Systems
Yahoo Finance · Oct 6
Charles River Laboratories (CRL) Stock Fair Value Rises After Analyst Day Target Increases
Yahoo Finance · Oct 2
Animal Model - Global Strategic Business Report: Market Size to Surge to $3.6 Billion by 2032 as CRISPR Disrupts R&D - Benchmark Charles River, Biocytogen, Crown Bioscience, Cyagen and The Jackson Laboratory
Yahoo Finance · Sep 30
Demand Stabilization Fuels Charles River Laboratories International’s (CRL) Recovery
Yahoo Finance · Sep 29
Pharmaceutical Impurity Synthesis and Isolation Services Report: Capitalize on a $2.1 Billion Market by 2030 as Tariffs and 8.9% Isolation Growth Reshape Competition Across Eurofins, WuXi AppTec, Cambrex and Charles River
Yahoo Finance · Sep 29
Computer-Aided Drug Discovery - Global Strategic Business Report: Capitalize on 11% CAGR as AI-led CADD surges from $3.2B in 2025 to $6.7B by 2032—benchmark Bayer, Charles River Laboratories, Pharmaron and Chemical Computing Group to secure growth.
Yahoo Finance · Sep 29
Headlines via Yahoo Finance · links open the source · not an endorsement.
Recent SEC filings
8-K Sep 24, 2026 View → 10-Q Aug 5, 2026 View → 8-K Aug 5, 2026 View → 8-K May 11, 2026 View → 10-Q May 7, 2026 View →
Source: SEC EDGAR · opens the official filing.
Research & reports
External resources — availability and opinions are theirs, not ours.
This is reference data for your own analysis — not a recommendation to buy or sell CRL. Try it in the Lab to size a position and see the risk.